Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
37 results
D2.437 - Long-Term Analysis of the Phase 2 Open-Label Extension of Donidalorsen in Patients With Hereditary Angioedema
D2.436 - Application Study on the prevention and treatment of spleen aminopeptide oral solution on seasonal allergic rhinitis
D2.438 - Adipose-derived stem cells secretome attenuates eosinophilic inflammation in a chronic rhinosinusitis with nasal polyps mouse model
D2.439 - Low vitamin D levels in patients with allergic rhinitis and its supplementation
D2.440 - Burden of disease and patient preference in Hereditary Angioedema: findings from a mixed methods survey of carers and patients in the United Kingdom
- D3.100 - Risk Factors and Biomarkers for COVID-19 and Allergic Diseases
- D3.102 - PROMs Improvement Effects of Biologics in Chronic Rhinosinusitis with Nasal Polyps Patients: Real-life Experience
- D3.103 - Impact of aspirin-induced bronchospasm on the in vitro Aspirin Hypersensitivity Diagnostic Index in the patients with Aspirin Exacerbated Respiratory Disease
- D3.104 - A step towards standardized Clinical Remission Criteria for Chronic Rhinosinusitis with Nasal Polyps (CRSwNP): insights from a real-life study
- D3.105 - Suspected EGPA in a patient on Dupilumab treatment: confirmed diagnosis of sarcoidosis - case report
- D3.106 - Real-World Dupilumab Effectiveness Through 18 Months in Patients with CRSwNP and Coexisting Asthma: Results from the Global AROMA Registry
- D3.108 - PTGDR2 Blood Expression as a Potential Biomarker for Predicting Super-Response to IL-5-Targeted Therapies in Severe Asthma
D3.109 - Lichen planus following dupilumab treatment in patients with severe asthma and nasal sinus polyposis
- D3.110 - Contribution of biotherapies in the reintroduction of NSAIDs in patients with moderate to severe asthma, hypersensitive to COX-1 inhibitor NSAIDs
- D3.111 - Lymphocyte profile and asthma control during the treatment with benralizumab in real life
- D3.112 - Role of nasal cytology in patients with bronchial asthma
- D3.113 - In silico system pharmacology modeling provides insights into a mechanism for greater potency of TSLP/TSLPR pathway inhibition with verekitug, a novel antibody antagonist of TSLPR, as compared to tezepelumab
- D3.99 - Early Real-World Outcomes of Tezepelumab in Severe Asthma Patients Unresponsive to Prior Biologics
D3.373 - Hives and hidden codes: detection of miRNA in chronic spontaneous urticaria patients - pilot study
D3.369 - Childhood exhaled nitric oxide levels predict new-onset allergic rhinitis in adolescence and young adulthood
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download